The bisphosphonate alendronate (Binosto and Fosamax) can effectively maintain the gains in bone mineral density achieved with a year-long course of denosumab treatment in 91 percent of 126 patients who participated in a randomized clinical trial presented this week at the American Society for Bone and Mineral Research annual meeting in Orlando.
Rheumatology Network Editorial Staff
Patients with atrial fibrillation are commonly prescribed oral anticoagulants for stroke prevention, but in older patients at risk for osteoporosis, treatment with blood thinners may heighten osteoporosis risk, according to a study presented this week at the American Society for Bone and Mineral Research annual meeting in Orlando.
The cost of treating osteoporosis in the United states has risen 118 percent over the last 19 years, shows an analysis presented this week at the American Society for Bone and Mineral Research annual meeting in Orlando.
Taking calcium supplements doesn't appear to worsen cardiovascular health in healthy postmenopausal women, according to a study presented at the American Society for Bone and Mineral Research annual meeting that took place over the weekend.
In today's news roundup, we focus on recent advances made in osteoarthritis that touch on cardiovascular issues, bone spurs and treatment modalities.
Janssen is seeking FDA approval of guselkumab (Tremfya) for adults with active psoriatic arthritis. If approved, it would become the second IL-23 inhibitor in the U.S. market.
A 33-year-old man visits his doctor complaining of a thick scaly plaque on his toes and toenails and low back pain. What's your diagnosis?
In this installment of the psoriatic arthritis quiz, we focus on nail pitting and onycholysis. How familiar are you with the characteristics associated with these two conditions?
Controlling drug costs, optimal infliximab dosage, new treatment guidelines and more in today's rheumatology news update
In today's news roundup from Rheumatology Network, we highlight the week's most popular stories.
Affordability is a leading cause of drug abandonment among rheumatology patients. Back in April, the American College of Rheumatology issued a series of position statements designed to control drug costs while improving patient outcomes.